Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay
NCT ID: NCT00839202
Last Updated: 2017-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
7 participants
INTERVENTIONAL
2006-09-30
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
NCT00178607
Study Evaluating ReFacto in Hemophilia A
NCT00038909
Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A
NCT00038935
Improved Factor VIII Inhibitor Evaluation
NCT02726139
Cooperative Study of Factor VIII Inhibitors
NCT00000582
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FVIII immuno-assay
The study is not designed as a therapeutic evaluation, but an assessment of clotting factor VIII timed responses after the infusion of specified doses of licensed clotting factor VIII concentrates. The purpose of the study is to measure the levels of infused licensed clotting factor VIII by standard assay techniques and comparing these standard assays with an experimental assay. Measurements of possible co-factors that might impact the results were also carried out.
FVIII immuno-assay
There is no intervention. This is a study of the differences in assays.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FVIII immuno-assay
There is no intervention. This is a study of the differences in assays.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* factor VIII less that 2%
* informed consent signed
* absence of an inhibitor
Exclusion Criteria
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Vermont
OTHER
Children's Hospital Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Edward Gomperts
Attending Hematologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward D Gomperts, MD
Role: PRINCIPAL_INVESTIGATOR
Children's Hospital Los Angeles
Kenneth G Mann, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Vermont
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Biochemistry University of Vermont
Burlington, Vermont, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCI-06-0069-CR002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.